Epitalon

No — it's not an FDA-approved drug and isn't sold at retail pharmacies. There is no approved label for it to be prescribed off; licensed clinicians prescribe it and compounding pharmacies prepare it. Its regulatory status moved in July 2026. The FDA had removed it from the Category 2 list in spring, then told its Pharmacy Compounding Advisory Committee that Epitalon should not go on the 503A list. On July 24 the committee disagreed and voted 7–4–1 to recommend it, for insomnia. A recommendation is advice, not a rule — the FDA still has to write one — so confirm current availability with your provider.

Compounding it on a prescription is now tolerated, under conditions, though it is still on no list that authorises it. Section 503A lets a pharmacy compound only from an ingredient of an FDA-approved drug, a substance with a USP monograph or one on the FDA's 503A bulks list, and Epitalon is none of these. On October 28, 2026, HHS said it will not take action against State-licensed pharmacies and licensed physicians that compound Epitalon for a named patient while the FDA decides whether to list it. The conditions: Epitalon is the only active ingredient, the route is subcutaneous or intramuscular injection, in intermittent courses, the bulk substance comes from an FDA-registered manufacturer named on a certificate of analysis, and serious side effects are reported to the FDA. HHS can withdraw the policy. A blend that mixes Epitalon with other peptides is outside it, and buying from "research chemical" sellers without a prescription is still not a lawful supply route for human use. Since November 2, 2026, LegitScript, the certifier whose seal many telehealth sites show, no longer refuses certification to sellers whose Epitalon meets these conditions; that seal is not FDA approval.

Published clinical studies report minimal side effects at standard doses. The most common early reports are mild fatigue or changes in sleep architecture as circadian rhythms adjust. Serious adverse events have been rare in the studies to date. As with any longevity protocol, discuss your full medical history — particularly any cancer history or family risk — with your provider before starting.

Nobody knows. There is no long-term human safety data on Epitalon and no pharmacovigilance program outside Russia, so an interaction profile has never been built — the absence of reported problems is not the same as evidence of safety. One concern does have mechanistic grounding: Epitalon lengthens telomeres in cancer cells through a non-telomerase pathway, and whether that matters for someone with an undiagnosed tumour has not been studied. Disclose your full medication and supplement list to your provider, particularly if you are on immunosuppressants or cancer therapies.

The sellers in the price table on this page price it per vial or unit rather than by the month, each with the date we read it. Epitalon is dosed in short courses rather than continuously, so a monthly figure would not describe the bill. It is compounded to order, it was recommended for the 503A list by an FDA advisory committee in July 2026 without the agency having acted, and providers quote it per course. What you pay over a year depends on how many courses you run; most protocols call for two to four. Ask for the per-course price in writing. Insurance does not cover it.